{"id":"pf-07836396-influenza-sarna","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Monitor","effect":"Decreased atazanavir levels"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased darunavir levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased lopinavir levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased ritonavir levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased saquinavir levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Decreased tipranavir levels"}],"commonSideEffects":[],"contraindications":["Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.","History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.","Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.","Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.","Women who are pregnant or breastfeeding.","Allergy to egg proteins (egg or egg products) or chicken proteins.","Participant who has had significant exposure to laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 infection), coronavirus disease 2019 (COVID-19), or influenza in the past 14 days known prior to Visit 1","Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or","Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention","Vaccination with any influenza vaccine within 6 months (175 days) before study intervention administration.","Any participant who has received or plans to receive a nucleoside-modified messenger ribonucleic acid","Previous vaccination with an saRNA or an alphavirus replicon vaccine preparation.","Participation in other studies involving study intervention within 28 days prior to study entry and/or during study","Screening hematology/blood chemistry lab >=Grade 1 abnormality. Except Bilirubin, other stable Grade1 abnormalities","Screening electrocardiogram (ECG) that is consistent with probable or possible myocarditis or pericarditis, or","PF-07836391 Influenza saRNA, low dose"],"specialPopulations":{"Pregnancy":"Female participants who are not of childbearing potential; or male participant not able to father children.","Geriatric use":"","Paediatric use":"","Renal impairment":"","Hepatic impairment":""}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07836396-influenza-sarna","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:36:47.630643+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:36:54.026295+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:36:47.702272+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07836396-influenza-sarna","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:36:54.781968+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:55.992255+00:00"}},"allNames":"pf-07836396 influenza sarna","offLabel":[],"timeline":[],"aiSummary":"PF-07836396 Influenza saRNA is a marketed drug by Pfizer Inc. for Influenza. It has a revenue of $63.6B. The mechanism of action is not specified. It has one clinical trial and no publications. This drug is a first-in-class treatment for Influenza.","brandName":"PF-07836396 Influenza saRNA","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"first-in-class","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for PF-07836396 Influenza saRNA involves targeting the influenza virus. However, the specific molecular target and pharmacological class are not specified. This lack of information makes it challenging for healthcare professionals to fully understand the drug's effects and potential interactions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07836396-influenza-sarna","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07836396-influenza-sarna","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:36:57.897940+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"SARS-CoV-2 saRNA vaccine","company":"Not specified","advantage":"Preclinical trials showed protection against lethal heterologous infections"},{"name":"Influenza virus saRNA vaccine","company":"Not specified","advantage":"Preclinical tests showed high, specific antibody and T cell responses, and protection of mice"},{"name":"Respiratory syncytial virus saRNA vaccine","company":"Not specified","advantage":"Preclinical tests showed high, specific antibody and T cell responses"},{"name":"Rabies virus saRNA vaccine","company":"Not specified","advantage":"Preclinical tests showed high, specific antibody and T cell responses"},{"name":"Zika virus saRNA vaccine","company":"Not specified","advantage":"Preclinical tests showed high, specific antibody and T cell responses"},{"name":"Ebola virus saRNA vaccine","company":"Not specified","advantage":"Preclinical tests showed high, specific antibody and T cell responses"},{"name":"VEEV saRNA vaccine","company":"Not specified","advantage":"Preclinical tests showed high, specific antibody and T cell responses"},{"name":"HIV-1 saRNA vaccine","company":"Not specified","advantage":"Preclinical tests showed high, specific antibody and T cell responses"}],"genericName":"pf-07836396-influenza-sarna","indications":{"approved":[{"name":"Influenza","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440}],"_emaApprovals":[{"date":"","name":"PF-07836396 Influenza saRNA","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2109042"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:36:57.897940+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}